Pipeline

BIAL’s medicines are already making a real difference to the lives of people all over the world. We are focused on neurosciences and cardiovascular areas.

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed

BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Adjunct</div>
100%
BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Paediatric</div>
100%
BIA 2-093 - Eslicarbazepine Ac. <div>Epilepsy - Monotherapy</div>
100%
BIA 9-1067 - Opicapone <div>Parkinson’s Disease</div>
100%
BIA 21 <div>Cardiovascular</div>
10%
BIA 24 <div>CNS</div>
5%
BIA 26 <div>CNS</div>
2%
BIA 27 <div>CNS</div>
2%
BIA 28-6156 <div>Parkinson’s Disease (GBA mutations)</div>
35%
BIA 29 <div>Parkinson’s Disease</div>
4%
BIA 30 <div>Parkinson’s Disease</div>
2%
BIA 31 <div>Parkinson’s Disease</div>
2%
BIA 32 <div>Parkinson’s Disease</div>
5%

BIA-28

×

You are now navigating away from the BIAL website.

BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.

CANCEL CONTINUE